Abbott announces positive trial results

Abbott Laboratories has announced “encouraging” results following clinical trials involving its ZoMaxx Drug-Eluting Coronary Stent System.

The results emerged from a 40-patient, single-arm, clinical, angiographic and intravascular ultrasound (IVUS) trial, which was carried out to ascertain the effectiveness of the system for treating coronary heart disease.

“The results of the ZoMaxx IVUS study are encouraging as they demonstrated that controlled release of zotarolimus minimised neointimal proliferation over the first four months following stent implantation,” said Dr Alexandre Abizaid Instituto Dante Pazzannese, Sao Paulo, Brazil, principal investigator of the Zomaxx IVUS clinical trial.

“The ZoMaxx stent is a highly deliverable device that is easy to see under X-ray. It shows promise as a percutaneous treatment for patients with coronary artery disease.”

The 100 per cent procedural success from the trial was also encouraging for Abbott, as was the fact that there were no adverse cardiac events following or during the use of the system.

Abbott’s system is used for proprietary application of drugs and inert coatings.

© Adfero Ltd